Injury, Occupational Diseases, Poisoning
Conditions
Interventions
EchiTab ICP Plus antivenom
Sponsors
Venom Antivenom Research Project Bayero University Kano
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1- Children aged 12 months to 12 years 2- Availability of intravenous access 3- Mild to moderately envenomed patients 4- Presentation within 72 hours of bite
Exclusion criteria
Exclusion criteria: 1- Severely envenomed sick children that are or have: a. Collapsed or in unresponsive shock b. Grade III of the snakebite severity score c. Severe anaemia with packed cell volume (PCV) less than 12% d. Non-transient unconscious patients e. Patients with severe delayed gangrenous body part f. Suspicion of acute end-organ complications e.g., acute kidney injury (AKI) g. Other 2- Inability to obtain intravenous access for antivenom administration or blood collection 3- Children less than 12 months 4- Other severe co-morbidities
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1-Proportion who achieve restoration of blood clotting following 20WBCT at 6 hours and at 12 hours post antivenom administration 2-Proportion who develop features of early adverse reactions (EAR) post antivenom administration(s); patients will be actively observed for 60 minutes post administration | — |
Secondary
| Measure | Time frame |
|---|---|
| 1- The enrolled patients will be assessed for size of the bitten limb compared to the non-bitten limb pre-antivenom administration and thereafter daily. 2- Length of hospital stay in days and hours will recorded 3- All patients who die or develop life threatening complications (e.g., limb amputation) will be recorded 4- Proportion who develop late serum reactions in all enrolled groups 5- ELISA measurements of venom antigen and antivenom antibody (or fragment) level | — |
Countries
Nigeria
Contacts
Public ContactHamza Muhammad
Associate Professor of Medicine
Outcome results
None listed